Modern Retina

2 days ago | modernretina.com | Hattie Hayes |Martin Harp |Alfredo A. Sadun

During the recent Association for Research in Vision and Ophthalmology (ARVO) meeting, Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared some exciting new research with the Eye Care Network. In Salt Lake City, Utah, Prof. Sadun detailed a recent project examining Leber hereditary optic neuropathy (LHON).

4 days ago | modernretina.com | Sydney M Crago

May 11, 2025Katherine Talcott, a retina specialist at Cole Eye Institute at the Cleveland Clinic, presented at the Retinal World Congress 2025 meeting. In her presentation and in her conversation with Modern Retina, Talcott discussed the connection between autoimmune diseases and age-related macular degeneration (AMD), emphasizing the role of inflammation in AMD development. The following conversation has been edited lightly for clarity.

5 days ago | modernretina.com | Sydney M Crago

May 10, 2025Alan J. Franklin, MD, PhD, spoke with Modern Retina at Retina World Congress 2025. This meeting is taking place in Fort Lauderdale, Florida, from May 8-11, 2025. In this conversation, Franklin discussed a research study on intraoperative fluorescein angiography in surgical procedures, highlighting significant advancements in surgical visualization and patient outcomes. The following transcript has been edited lightly for clarity.

5 days ago | modernretina.com | Sydney M Crago

At the Retina World Congress 2025 in Lauderdale, Florida, Dilsher S. Dhoot, MD, from Retina Consultants of America in Santa Barbara, California shared research on the pharmaceutical candidate, OTX-TKI which is being evaluated as a potential treatment for diabetic retinopathy. The presentation focused on the HELIOS trial, which demonstrated promising results for a potential new treatment approach. The study showed that OTX-TKI was well-tolerated and safe, with no serious adverse events reported.

1 week ago | modernretina.com | Sydney M Crago

May 8, 2025Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients. Beacon Therapeutics has released 6-month interim safety and efficacy results from the Phase 2 DAWN (NCT06275620) trial for the pharmaceutical candidate laru-zova (laruparetigene zovaparvovec). This candidate is being evaluated for treatment of patients with X-linked retinitis pigmentosa (XLRP).